Peer reply pharmacy DB6
Peer: Sharon
Nice job in your submit! You offered an intensive evaluation of the affected person case and made applicable medicine suggestions primarily based on present tips. You additionally offered rationale in your suggestions, which is vital for a pharmacist to do when speaking with different healthcare suppliers.
I agree along with your alternative of lisinopril for hypertension administration. As you talked about, ACE inhibitors have been proven to be efficient in lowering cardiovascular morbidity and mortality in sufferers with hypertension and coronary heart failure. Moreover, on this explicit affected person case, the presence of proteinuria signifies that the affected person might have underlying renal illness. ACE inhibitors have been proven to be renoprotective in sufferers with proteinuria, making lisinopril a good selection for this affected person (Nationwide Kidney Basis, 2021).
You additionally accurately recognized that this affected person has a historical past of smoking and may due to this fact be suggested to give up. Smoking cessation is a vital element of lowering the chance of heart problems and bettering general well being outcomes in sufferers with hypertension (Jindal & Gupta, 2019). Moreover, smoking cessation may also help sluggish the development of renal illness in sufferers with proteinuria (Jha et al., 2019).
Total, your submit demonstrated your information of hypertension administration and your means to use that information to a affected person case. Nice job!
References:
Jha, V., Wang, A. Y. M., Wang, H., & Huang, C. (2019). Persistent kidney illness. The Lancet, 393(10184), 172-184. doi: 10.1016/S0140-6736(18)32288-X
Jindal, S., & Gupta, R. (2019). Smoking Cessation in Hypertension. Present Hypertension Studies, 21(2). doi: 10.1007/s11906-019-0924-4
Nationwide Kidney Basis. (2021). KDIGO 2021 Scientific Apply Guideline for the Administration of Blood Stress in Persistent Kidney Illness. Retrieved from https://www.kidney.org/sites/default/files/02-11-8211_Hypertension%20Guideline_WEB_0.pdf